Innoviva Inc
$ 21.42
-2.15%
29 May - close price
- Market Cap 1,633,388,000 USD
- Current Price $ 21.42
- High / Low $ 21.91 / 21.26
- Stock P/E 3.54
- Book Value 18.18
- EPS 6.26
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.51 %
- 52 Week High 25.14
- 52 Week Low 16.52
About
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
Analyst Target Price
$35.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-06 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-11-01 | 2023-08-02 |
| Reported EPS | 0.47 | 1.944 | 0.38 | 0.77 | -0.7429 | 0.26 | 0.12 | -0.55 | 0.46 | 0.76 | 0.18 | 0.02 |
| Estimated EPS | 0.43 | 0.574 | 0.39 | 0.5 | 0.33 | 0.41 | 0.27 | 0.24 | 0.17 | 0.23 | 0.27 | 0.26 |
| Surprise | 0.04 | 1.37 | -0.01 | 0.27 | -1.0729 | -0.15 | -0.15 | -0.79 | 0.29 | 0.53 | -0.09 | -0.24 |
| Surprise Percentage | 9.3023% | 238.676% | -2.5641% | 54% | -325.1212% | -36.5854% | -55.5556% | -329.1667% | 170.5882% | 230.4348% | -33.3333% | -92.3077% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.5 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|
| Payment Date | None | None | None | None | None | None |
| Amount | $0.25 | $0.25 | $0.25 | $0.25 | $0.25 | $5.571428571 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: INVA
2026-05-26 22:12:16
BTIG analyst Julian Harrison has reiterated a "Buy" rating for Innoviva (INVA), maintaining a price target of $42.00, despite the stock currently trading at $22.46, indicating it is 10.9% overvalued according to GuruFocus's GF Value™. Innoviva, a biopharmaceutical company with a $1.66 billion market cap, boasts a strong GF Score™ of 88/100, reflecting robust financial strength and profitability. However, investors are cautioned due to the overvaluation and absence of recent insider trading activity.
2026-05-25 10:38:45
Innoviva Inc (INVA) has been identified as a strong value stock due to its high fundamental ratings across valuation, profitability, health, and growth metrics. The company boasts a cheap valuation with a P/E of 6.01, robust profitability shown by a 119.88% profit margin, excellent financial health with a high Current Ratio, and promising future growth prospects. This combination makes INVA an attractive opportunity for value investors seeking stability and potential upside.
2026-05-25 01:10:27
This article from Stock Traders Daily analyzes the technical signals for Innoviva Inc. (NASDAQ: INVA), highlighting weak near and mid-term sentiment but a strong long-term outlook. It identifies resistance testing, an exceptional short setup with a 29.0:1 risk-reward ratio, and provides AI-generated institutional trading strategies for long, breakout, and short positions based on different risk profiles. The analysis also details support and resistance levels across various time horizons.
2026-05-22 20:39:19
Innoviva, Inc.'s Chief Accounting Officer, Marianne Zhen, had 1,127 shares of common stock withheld by the company to cover income tax obligations related to the quarterly vesting of prior equity grants. This transaction, executed on May 20, 2026, at $22.24 per share, was a tax-withholding disposition and not an open-market sale. Following this, Zhen directly holds 57,516 shares of Innoviva common stock.
2026-05-22 20:39:19
Innoviva, Inc.'s CFO, Stephen Basso, engaged in routine equity activities, acquiring 1,123 shares through the company's Employee Stock Purchase Plan (ESPP) on May 15, 2026. Subsequently, on May 20, 2026, 559 shares were withheld to cover income taxes related to the vesting of prior equity awards, an action that is not considered an open-market sale. After these transactions, Basso directly holds 88,571 shares of Innoviva common stock.
2026-05-22 20:39:19
Innoviva, Inc. CEO Pavel Raifeld reported routine equity compensation activity through a Form 4 filing. On May 15, he acquired 1,123 shares of common stock at no cost via the Employee Stock Purchase Plan, and on May 20, 1,130 shares were withheld by Innoviva to cover income taxes on previously granted equity awards. Following these transactions, Raifeld directly holds 285,929 shares of Innoviva.
